Analyzing Brainstorm Cell Therapeutics (BCLI) and Ionis Pharmaceuticals (IONS)
Brainstorm Cell Therapeutics (NASDAQ: BCLI) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
This table compares Brainstorm Cell Therapeutics and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-56.24%||-51.18%|
This is a summary of current ratings and price targets for Brainstorm Cell Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||1||0||3.00|
Brainstorm Cell Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 115.83%. Ionis Pharmaceuticals has a consensus target price of $49.46, suggesting a potential downside of 16.49%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Ionis Pharmaceuticals.
Institutional and Insider Ownership
12.7% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 89.3% of Ionis Pharmaceuticals shares are owned by institutional investors. 23.7% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 1.9% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Brainstorm Cell Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 3.13, meaning that its stock price is 213% more volatile than the S&P 500.
Earnings and Valuation
This table compares Brainstorm Cell Therapeutics and Ionis Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||N/A||-$5.06 million||($0.28)||-14.89|
|Ionis Pharmaceuticals||$485.73 million||15.16||$80.88 million||$0.21||282.06|
Ionis Pharmaceuticals has higher revenue and earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals beats Brainstorm Cell Therapeutics on 9 of the 12 factors compared between the two stocks.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.